04:44 PM EDT, 06/25/2025 (MT Newswires) -- Maravai LifeSciences ( MRVI ) said it appointed Rajesh Asarpota as its chief financial officer, starting June 30.

Asarpota will succeed CFO Kevin Herde, who will transition into an advisory role to support a smooth handover, the company said late Wednesday.

Asarpota joins Maravai with almost 30 years of experience, including 10 years as CFO of public and private life sciences and medical device companies. His arrival follows the recent chief executive officer transition to Bernd Brust, forming a refreshed executive team.

Asarpota's previous roles include CFO at NuVasive, Questcor Pharmaceuticals, and, most recently, Augmedics.

As previously announced, Maravai reiterated that it is neither reaffirming nor withdrawing its full-year 2025 financial guidance at this time. The company will reassess its outlook during its Q2 earnings call in August, following a "comprehensive business review" by Brust and Asarpota.